Hengrui/Kailera's GLP-1 pill HRS-7535 met obesity & diabetes China trial endpoints but showed high nausea & vomiting, raising concerns vs Lilly & Novo pills.
July 7, 2026 11:25 AM EDTUpdated 12:19 PM
Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
The GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side…
Kailera Therapeutics oral GLP-1 meets Phase 3 targets for obesity and diabetes. KLRA stock falls 9% on reported GI side effects.
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how…
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with…
Kailera's GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The Readout
An experimental GLP-1 pill helped people with obesity or overweight lose as much as 12.1% of their body weight in just 36 weeks.…
